Mutually exclusive FGFR2, HER2, and KRAS gene amplifications in gastric cancer revealed by multicolour FISH

Cancer Letters

Volumn 353, Issue 2, 2014, Pages 167-175

  Das, Kakoli ^a   Gunasegaran, Bavani ^a   Tan, Iain Beehuat ^b,c   Deng, Niantao ^a   Lim, Kiat Hon ^d   Tan, Patrick ^a,c,e,f  

^a DUKE NUS MEDICAL SCHOOL   (Singapore)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^c GENOME INSTITUTE OF SINGAPORE   (Singapore)

^d SINGAPORE GENERAL HOSPITAL   (Singapore)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^f INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

Author keywords

FGFR2; Gastric cancer; Gene amplification; HER2; KRAS; Multicolour FISH

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 2; PROTEIN TYROSINE KINASE; RAS PROTEIN; ERBB2 PROTEIN, HUMAN; FGFR2 PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; ONCOPROTEIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GRADING; CONTROLLED STUDY; COPY NUMBER VARIATION; FEASIBILITY STUDY; FEMALE; FGFR2 GENE; FLUORESCENCE IN SITU HYBRIDIZATION; GASTRIC CANCER CELL LINE; GENE AMPLIFICATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; HER2 GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTICOLOR FLUORESCENCE IN SITU HYBRIDIZATION; ONCOGENE K RAS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STOMACH BIOPSY; STOMACH CANCER; STOMACH CARCINOGENESIS; TUMOR XENOGRAFT; GENE DOSAGE; GENETICS; HER2; KAPLAN MEIER METHOD; KRAS; MIDDLE AGED; MORTALITY; MULTICOLOUR FISH; PATHOLOGY; STOMACH TUMOR;

FGFR2; GASTRIC CANCER; GENE AMPLIFICATION; HER2; KRAS; MULTICOLOUR FISH;

AGED; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; GENETIC ASSOCIATION STUDIES; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, ERBB-2; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84908673483     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.07.021     Document Type: Article

References (44)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin 2011, 61:69-90.
2. Meireles S.I., Cristo E.B., Carvalho A.F., Hirata R., Pelosof A., Gomes L.I., et al. Molecular classifiers for gastric cancer and nonmalignant diseases of the gastric mucosa. Cancer Res 2004, 64:1255-1265.
3. Crew K.D., Neugut A.I. Epidemiology of gastric cancer. World J. Gastroenterol 2006, 12:354-362.
4. Holmes K., Egan B., Swan N., O'Morain C. Genetic mechanisms and aberrant gene expression during the development of gastric intestinal metaplasia and adenocarcinoma. Curr. Genomics 2007, 8:379-397.
5. Pinheiro H., Bordeira-Carrico R., Seixas S., Carvalho J., Senz J., Oliveira P., et al. Allele-specific CDH1 downregulation and hereditary diffuse gastric cancer. Hum. Mol. Genet 2010, 19:943-952.
6. Fan B., Dachrut S., Coral H., Yuen S.T., Chu K.M., Law S., et al. Integration of DNA copy number alterations and transcriptional expression analysis in human gastric cancer. PLoS ONE 2012, 7:e29824.
7. Deng N., Goh L.K., Wang H., Das K., Tao J., Tan I.B., et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut 2012, 61:673-684.
8. Stella G.M., Scabini R., Inghilleri S., Cemmi F., Corso S., Pozzi E., et al. EGFR and KRAS mutational profiling in fresh non-small cell lung cancer (NSCLC) cells. J. Cancer Res. Clin. Oncol 2013, 139:1327-1335.
9. Di Nicolantonio F., Martini M., Molinari F., Sartore-Bianchi A., Arena S., Saletti P., et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J. Clin. Oncol 2008, 26:5705-5712.
10. Kunii K., Davis L., Gorenstein J., Hatch H., Yashiro M., Di Bacco A., et al. FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival. Cancer Res 2008, 68:2340-2348.
11. Matsumoto K., Arao T., Hamaguchi T., Shimada Y., Kato K., Oda I., et al. FGFR2 gene amplification and clinicopathological features in gastric cancer. Br. J. Cancer 2012, 106:727-732.
12. Hattori Y., Itoh H., Uchino S., Hosokawa K., Ochiai A., Ino Y., et al. Immunohistochemical detection of K-sam protein in stomach cancer. Clin. Cancer Res 1996, 2:1373-1381.
13. Toyokawa T., Yashiro M., Hirakawa K. Co-expression of keratinocyte growth factor and K-sam is an independent prognostic factor in gastric carcinoma. Oncol. Rep 2009, 21:875-880.
14. Heiskanen M., Kononen J., Barlund M., Torhorst J., Sauter G., Kallioniemi A., et al. CGH, cDNA and tissue microarray analyses implicate FGFR2 amplification in a small subset of breast tumors. Anal. Cell. Pathol 2001, 22:229-234.
15. Shin E.Y., Lee B.H., Yang J.H., Shin K.S., Lee G.K., Yun H.Y., et al. Up-regulation and co-expression of fibroblast growth factor receptors in human gastric cancer. J. Cancer Res. Clin. Oncol 2000, 126:519-528.
16. Turner N., Lambros M.B., Horlings H.M., Pearson A., Sharpe R., Natrajan R., et al. Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene 2010, 29:2013-2023.
17. Koeppen H.K., Wright B.D., Burt A.D., Quirke P., McNicol A.M., Dybdal N.O., et al. Overexpression of HER2/neu in solid tumours: an immunohistochemical survey. Histopathology 2001, 38:96-104.
18. Takehana T., Kunitomo K., Kono K., Kitahara F., Iizuka H., Matsumoto Y., et al. Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay. Int. J. Cancer 2002, 98:833-837.
19. Gravalos C., Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann. Oncol 2008, 19:1523-1529.
20. Jorgensen J.T. Targeted HER2 treatment in advanced gastric cancer. Oncology 2010, 78:26-33.
21. Bang Y.J., Van Cutsem E., Feyereislova A., Chung H.C., Shen L., Sawaki A., et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010, 376:687-697.
22. Fujimoto-Ouchi K., Sekiguchi F., Yasuno H., Moriya Y., Mori K., Tanaka Y. Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemother. Pharmacol 2007, 59:795-805.
23. Forbes S.A., Bindal N., Bamford S., Cole C., Kok C.Y., Beare D., et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 2011, 39:D945-D950.
24. van Grieken N.C., Aoyma T., Chambers P.A., Bottomley D., Ward L.C., Inam I., et al. KRAS and BRAF mutations are rare and related to DNA mismatch repair deficiency in gastric cancer from the East and the West: results from a large international multicentre study. Br. J. Cancer 2013, 108:1495-1501.
25. Nagarajan N., Bertrand D., Hillmer A.M., Zang Z.J., Yao F., Jacques P.E., et al. Whole-genome reconstruction and mutational signatures in gastric cancer. Genome Biol 2012, 13:R115.
26. Wagner P.L., Stiedl A.C., Wilbertz T., Petersen K., Scheble V., Menon R., et al. Frequency and clinicopathologic correlates of KRAS amplification in non-small cell lung carcinoma. Lung Cancer 2011, 74:118-123.
27. Birkeland E., Wik E., Mjos S., Hoivik E.A., Trovik J., Werner H.M., et al. KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer. Br. J. Cancer 2012, 107:1997-2004.
28. Greene F.L. American Joint Committee on Cancer. American Cancer Society Springer 2002, SP-Verlag, New York.
29. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol. Microbiol. Scand 1965, 64:31-49.
30. Fred F.C., Bosman T., Hruban R.H., Theise N.D. WHO classification of tumours of the digestive system. WHO Classification of Tumours 2010, IARC, Lyon. E.S.J. Fred, T. Bosman, S.R. Lakhani, H. Ohgaki (Eds.).
31. Speicher M.R., Gwyn Ballard S., Ward D.C. Karyotyping human chromosomes by combinatorial multi-fluor FISH. Nat. Genet 1996, 12:368-375.
32. Schrock E., du Manoir S., Veldman T., Schoell B., Wienberg J., Ferguson-Smith M.A., et al. Multicolor spectral karyotyping of human chromosomes. Science 1996, 273:494-497.
33. Tanke H.J., Wiegant J., van Gijlswijk R.P., Bezrookove V., Pattenier H., Heetebrij R.J., et al. New strategy for multi-colour fluorescence in situ hybridisation: COBRA: COmbined Binary RAtio labelling. Eur. J. Hum. Genet 1999, 7:2-11.
34. Henegariu O., Heerema N.A., Bray-Ward P., Ward D.C. Colour-changing karyotyping: an alternative to M-FISH/SKY. Nat. Genet 1999, 23:263-264.
35. Muller S., Rocchi M., Ferguson-Smith M.A., Wienberg J. Toward a multicolor chromosome bar code for the entire human karyotype by fluorescence in situ hybridization. Hum. Genet 1997, 100:271-278.
36. Chudoba I., Plesch A., Lorch T., Lemke J., Claussen U., Senger G. High resolution multicolor-banding: a new technique for refined FISH analysis of human chromosomes. Cytogenet. Cell Genet 1999, 84:156-160.
37. Keedy V.L., Temin S., Somerfield M.R., Beasley M.B., Johnson D.H., McShane L.M., et al. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J. Clin. Oncol 2011, 29:2121-2127.
38. Kim H.K., Choi I.J., Kim C.G., Kim H.S., Oshima A., Yamada Y., et al. Three-gene predictor of clinical outcome for gastric cancer patients treated with chemotherapy. Pharmacogenomics J. 2012, 12:119-127.
39. Peng D.F., Sugihara H., Mukaisho K., Tsubosa Y., Hattori T. Alterations of chromosomal copy number during progression of diffuse-type gastric carcinomas: metaphase- and array-based comparative genomic hybridization analyses of multiple samples from individual tumours. J. Pathol 2003, 201:439-450.
40. Nakatani H., Sakamoto H., Yoshida T., Yokota J., Tahara E., Sugimura T., et al. Isolation of an amplified DNA sequence in stomach cancer. Cancer Sci 1990, 81:707-710.
41. Yokota J., Yamamoto T., Miyajima N., Toyoshima K., Nomura N., Sakamoto H., et al. Genetic alterations of the c-erbB-2 oncogene occur frequently in tubular adenocarcinoma of the stomach and are often accompanied by amplification of the v-erbA homologue. Oncogene 1988, 2:283-287.
42. Su X., Zhan P., Gavine P.R., Morgan S., Womack C., Ni X., et al. FGFR2 amplification has prognostic significance in gastric cancer: results from a large international multicentre study. Br. J. Cancer 2014, 110:967-975.
43. Almendro V., Marusyk A., Polyak K. Cellular heterogeneity and molecular evolution in cancer. Annu. Rev. Pathol 2013, 8:277-302.
44. Gerlinger M., Rowan A.J., Horswell S., Larkin J., Endesfelder D., Gronroos E., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med 2012, 366:883-892.